URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Mary Elizabeth Henderson net worth and biography

Mary Henderson Biography and Net Worth

SVP, Technical Operations of Jazz Pharmaceuticals

Liz Henderson was appointed senior vice president, Technical Operations in August 2023. Ms. Henderson has extensive experience in commercial leadership roles at the regional and global level in technical operations, global manufacturing and supply chain management. Throughout her career, she’s demonstrated a strong passion for helping patients across the world through advancements in technology.

Prior to joining Jazz, Ms. Henderson held various roles of increasing responsibility at Merck KGaA including executive vice president of Global Manufacturing & Supply Chain, senior vice president APAC Region & Healthcare Sustainability lead and managing director and general manager, UK & Republic of Ireland. Prior to her tenure at Merck KGaA, Ms. Henderson held manufacturing leadership roles at Amgen and Pfizer.

Ms. Henderson received a Bachelor of Science degree in Analytical Chemistry from Dublin City University, Ireland.

What is Mary Elizabeth Henderson's net worth?: The estimated net worth of Mary Elizabeth Henderson is at least $1.79 million as of September 6th, 2024. Ms. Henderson owns 14,531 shares of Jazz Pharmaceuticals stock worth more than $1,786,877 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Henderson may own. Learn More about Mary Elizabeth Henderson's net worth.
How do I contact Mary Elizabeth Henderson?: The corporate mailing address for Ms. Henderson and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Mary Elizabeth Henderson's contact information.
Has Mary Elizabeth Henderson been buying or selling shares of Jazz Pharmaceuticals?: Mary Elizabeth Henderson has not been actively trading shares of Jazz Pharmaceuticals during the past quarter. Most recently, Mary Elizabeth Henderson sold 1,410 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a transaction totalling $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company's stock, valued at $1,573,707.30. Learn More on Mary Elizabeth Henderson's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Mary Elizabeth Henderson Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/6/2024	Sell	1,410	$108.30	$152,703.00	14,531

Mary Elizabeth Henderson Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $122.97

$121.37

$124.39

50 Day Range

MA: $118.89

$108.05

$127.74

2 Week Range

Now: $122.97

$99.06

$134.17

Volume

1,767,343 shs

Average Volume

675,822 shs

Market Capitalization

$7.43 billion

P/E Ratio

17.32

Dividend Yield

N/A

Beta

0.57